Recombinant human cytochrome P450 monooxygenases for drug metabolite synthesis.

Cytochrome P450 monooxygenases (CYPs) are important enzymes in the metabolism of xenobiotics. Therefore, several approaches to clone and overexpress the human isoforms have been made. In addition to microsomes or S9 preparations, these recombinant human isoforms have found diverse application in drug development. We discuss and give examples of the use of bacterial whole cell systems with rec. human CYPs for the preparative scale synthesis of drug metabolites.

[1]  B. Brodie,et al.  Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. , 1954, The Journal of biological chemistry.

[2]  Y. Hiraoka,et al.  Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1. , 2002, Biochemistry.

[3]  F. Guengerich,et al.  Cytochrome p450 enzymes in the generation of commercial products , 2002, Nature Reviews Drug Discovery.

[4]  F. Guengerich,et al.  Cytochrome P450s and other enzymes in drug metabolism and toxicity , 2006, The AAPS Journal.

[5]  J. Ishikawa,et al.  Hydroxylation of Testosterone by Bacterial Cytochromes P450 Using the Escherichia coli Expression System , 2006, Bioscience, biotechnology, and biochemistry.

[6]  C. Wolf,et al.  Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: an intralaboratory comparison. , 1999, Drug metabolism reviews.

[7]  F. Peters,et al.  Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine. , 2009, Forensic science international.

[8]  M. White,et al.  A Predictably Selective Aliphatic C–H Oxidation Reaction for Complex Molecule Synthesis , 2007, Science.

[9]  F Peter Guengerich,et al.  Cytochromes P450, drugs, and diseases. , 2003, Molecular interventions.

[10]  Y. Uno,et al.  Bioconversion of small molecules by cytochrome P450 species expressed in Escherichia coli , 2008, Biotechnology and applied biochemistry.

[11]  F. Arnold,et al.  Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. , 2006, Biotechnology and bioengineering.

[12]  M. Berenbaum,et al.  Modifications in the N-terminus of an insect cytochrome P450 enhance production of catalytically active protein in baculovirus-Sf9 cell expression systems. , 2008, Insect biochemistry and molecular biology.

[13]  C. Wolf,et al.  Recombinant Yeast and Bacteria that Express Human P450s: Bioreactors for Drug Discovery, Development, and Biotechnology , 2007 .

[14]  R Scott Obach,et al.  Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. , 2009, Chemical research in toxicology.

[15]  K. Korzekwa,et al.  cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[16]  W. Humphreys,et al.  Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. , 2004, Journal of medicinal chemistry.

[17]  S. Surapaneni,et al.  Role of drug metabolism in drug discovery and development , 2001, Medicinal research reviews.

[18]  Magnus Ingelman-Sundberg,et al.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. , 2004, Trends in pharmacological sciences.

[19]  T. Rushmore,et al.  Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. , 2000, Metabolic engineering.

[20]  P. Beaune,et al.  Recombinant yeast in drug metabolism. , 1993, Toxicology.

[21]  T. Ahn,et al.  Functional expression of human cytochrome P450 enzymes in Escherichia coli. , 2006, Current drug metabolism.

[22]  C. Wolf,et al.  A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. , 1997, Archives of biochemistry and biophysics.

[23]  Imad Hanna,et al.  Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli , 2005, Journal of Industrial Microbiology and Biotechnology.

[24]  R. Bernhardt,et al.  Cytochromes P450 as versatile biocatalysts. , 2006, Journal of biotechnology.

[25]  S. Lütz,et al.  Challenges of steroid biotransformation with human cytochrome P450 monooxygenase CYP21 using resting cells of recombinant Schizosaccharomyces pombe. , 2010, Journal of biotechnology.

[26]  K. Auclair,et al.  Progress towards the easier use of P450 enzymes. , 2006, Molecular bioSystems.

[27]  V. Urlacher,et al.  Cytochrome P450 BM-3 Evolved by Random and Saturation Mutagenesis as an Effective Indole-Hydroxylating Catalyst , 2008, Applied biochemistry and biotechnology.

[28]  C. Wolf,et al.  In Vivo and In Vitro Recombinant DNA Technology as a Powerful Tool in Drug Development , 1999 .

[29]  Michael D. Coleman,et al.  Human Drug Metabolism , 2020 .

[30]  F. Gonzalez,et al.  The development of a human cell line stably expressing human CYP3A4: role in the metabolic activation of aflatoxin B1 and comparison to CYP1A2 and CYP2A3. , 1991, Carcinogenesis.